EUVIMEDEUVIMED entdecken
Crossref

Maximising efficacy in HER2-positive breast cancer: immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy

Ramesh Chaudhari iD, Vishva Patel iD, Bharti Malvi, Superb K Misra iD, Ashutosh Kumar iD

Journal of Materials Chemistry B · 2025

DOI: 10.1039/d4tb01090f ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Materials Chemistry B, 2025. Verfasst von Ramesh Chaudhari und 4 weiteren Autor:innen. Beteiligte Einrichtung: Biological & Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad 380009, Gujarat, India. ashutosh.…. Hauptthemen laut MEDLINE: Paclitaxel, MicroRNAs, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: Indian Council of Medical Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

An immunoliposome-based targeted delivery of paclitaxel and miR155 inhibitor to HER2-positive breast cancer cells. Preclinical studies reveal reduced tumor volume, apoptosis induction, and minimal toxicity, highlighting its therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelMicroRNAsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesLiposomesAntineoplastic AgentsHumansFemaleAnimalsCell ProliferationMiceApoptosisDrug Screening Assays, AntitumorCell Line, TumorMice, Nude

Substanzen

PaclitaxelMicroRNAsErb-b2 Receptor Tyrosine KinasesLiposomesAntineoplastic AgentsERBB2 protein, human

Autor:innen und Institutionen

  • Biological & Life Sciences, School of Arts & Sciences, Ahmedabad University, Central Campus, Navrangpura, Ahmedabad 380009, Gujarat, India. ashutosh.kumar@ahduni.edu.in.
  • Materials Engineering, Indian Institute of Technology Gandhinagar, Gujarat, India.

ORCID-Profile: Ramesh Chaudhari, Vishva Patel, Superb K Misra, Ashutosh Kumar

Förderung

  • Indian Council of Medical Research

Zitieren

APA

Chaudhari, R., Patel, V., Malvi, B., Misra, S. K., & Kumar, A. (2025). Maximising efficacy in HER2-positive breast cancer: immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy. Journal of Materials Chemistry B. https://doi.org/10.1039/d4tb01090f

Vancouver

Chaudhari R, Patel V, Malvi B, Misra SK, Kumar A. Maximising efficacy in HER2-positive breast cancer: immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy. Journal of Materials Chemistry B. 2025. doi:10.1039/d4tb01090f

BibTeX
@article{Chaudhari2025,
  author = {Chaudhari, Ramesh and Patel, Vishva and Malvi, Bharti and Misra, Superb K and Kumar, Ashutosh},
  title = {Maximising efficacy in HER2-positive breast cancer: immunoliposomal co-delivery of miR155 inhibitor and paclitaxel for targeted therapy},
  journal = {Journal of Materials Chemistry B},
  year = {2025},
  doi = {10.1039/d4tb01090f}
}
Kostenlos starten →